The Preferred Global Oncology and Specialty Generics Partner
- Lotus Reported Unaudited October Consolidated Revenues of NT$912 million, Marking a Nearly 10% YoY Growth Accumulated Unaudited Consolidated Revenue for the Frist Ten Months Recorded NT$14.45 billion, with 17.58% YoY Growth
- Lotus Hosts Third Quarter 2023 Results Investor Conference
- Lotus Achieves Historic Q3 2023 Results with YTD EPS Soaring to a Record NTD 14.19 Marking a 29% Year-on-Year Growth
Lotus is now a fast growing specialty generic company in Asia and also the largest pharma company in Taiwan. Our business model ensures competitive advantage through focused in-house capabilities and a network of partners for enhanced speed and flexibility. The company boasts a best in class R&D and manufacturing platform with headquarters in Taiwan.
Lotus produces and promotes a unique portfolio of high quality and difficult-to-make pharmaceutical products fueling our growth. Lotus has more than 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US and has more than 250 products in the market.
Board of Directors
Lotus’ board of directors consists of nine distinguished members with an exceptional knowledge and experience in the related fields to supervise the Company’s operation.
Leadership Team with Proven Track Record
Lotus’s leadership team is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of all stakeholders.